Detrimental effects of secondhand smoke exposure on infants with cystic fibrosis

Related Experiment Video

Updated: May 2, 2026

Impact Assessment of Repeated Exposure of Organotypic 3D Bronchial and Nasal Tissue Culture Models to Whole Cigarette Smoke
09:50

Impact Assessment of Repeated Exposure of Organotypic 3D Bronchial and Nasal Tissue Culture Models to Whole Cigarette Smoke

Published on: February 12, 2015

11.3K

Benjamin T Kopp1, Lisa Sarzynski, Sabrina Khalfoun

  • 1Section of Pediatric Pulmonology, Nationwide Children's Hospital, Columbus, Ohio; Center for Microbial Pathogenesis, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio.

Pediatric Pulmonology
|March 11, 2014
PubMed

Insights

Secondhand smoke (SHS) exposure in infants with cystic fibrosis (CF) is linked to poorer growth and increased respiratory issues. Early parental smoking cessation is crucial to prevent these complications.

Area of Science:

  • Pediatric Pulmonology
  • Environmental Health
  • Genetics and Disease

Background:

  • Secondhand smoke (SHS) exposure poses risks to children's respiratory, immune, and nutritional health.
  • Limited data exists on SHS effects in infants with cystic fibrosis (CF).

Purpose of the Study:

  • To investigate the impact of SHS exposure on growth, lung function, and microbiology in infants with CF.

Main Methods:

  • Retrospective chart review of 75 infants with CF from 2008-2012.
  • Comparison of growth, lung function, chest CT imaging, and microbiology between SHS-exposed and non-exposed infants at 4 and 12 months.

Main Results:

  • SHS-exposed infants with CF showed decreased growth between 4 and 12 months.
  • SHS exposure correlated with increased bronchodilator responsiveness and air trapping.
  • Increased detection of methicillin-resistant Staphylococcus aureus (MRSA) and anaerobic bacteria in SHS-exposed infants.

Conclusions:

  • SHS exposure in CF infants is associated with impaired growth and altered lung function.
  • SHS exposure increases the risk of MRSA and anaerobic bacterial colonization.
  • Urgent parental smoking cessation interventions are recommended to mitigate SHS-related complications in CF infants.
Abstract

Keywords:
nutritionpulmonary function testing, MRSAtobacco

More Related Videos

Studying Effects of Cigarette Smoke on Pseudomonas Infection in Lung Epithelial Cells09:15

Studying Effects of Cigarette Smoke on Pseudomonas Infection in Lung Epithelial Cells

Published on: May 11, 2020

5.5K
Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System06:07

Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System

Published on: October 22, 2020

6.7K

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
1.1K
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
48
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
40
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by...
1.8K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
657
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
5.0K